Clinical Trials/NCT06243185

NCT06243185RecruitingPhase 2

A Phase II Study of the CDK4/6 Inhibitor Dalpiciclib Combined With Letrozole in Unresectable Refractory or Resistant Recurrent HR+/HER2 - Gynecologic Solid Tumors

Fengzhi Feng1 site in 1 country30 target enrollmentStarted: November 17, 2023Last updated: February 6, 2024

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Recruiting
Sponsor
Enrollment: 30
Locations: 1
Primary Endpoint: 6-month PFS rate

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

This is a prospective, single-arm, single-center registry study to investigate 6-month progression-free survival with Dalpiciclib, a CDK4/6 kinase inhibitor, plus letrozole in patients with unresectable refractory or resistant recurrent HR-positive, HER2-negative gynecologic solid tumors." Dalpiciclib is a CDK4/6 kinase inhibitor that selectively inhibits the activity of CDK4/6 kinase, so that the complex with Cyclin D cannot phosphorylate the downstream Rb protein and prevent cells from entering the S phase from G1 phase, thereby inhibiting cell proliferation and anti-tumor effects.

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to 75 Years (Adult, Older Adult)
Sex: Female
Accepts Healthy Volunteers: No

Inclusion Criteria

•Female patients aged ≥18 years and ≤75 years;
•Women with pathologically confirmed HR-positive, HER2-negative ovarian cancer or uterine tumors (including but not limited to high-grade serous ovarian cancer, low-grade serous ovarian cancer, ovarian endometrioid cancer, endometrioid cancer, low -grade endometrial stromal sarcoma, and uterine leiomyosarcoma) with evidence of focal recurrence or metastasis; Non-curative surgical resection or radiation therapy failing standard treatment, and no standard chemotherapy regimen. Er-positivity and/or PR-positive tumor cells were defined as 1% or more of all tumor cells that stained positively (as confirmed by the site investigator). Her2-negative was defined as 0/1+ on standard immunohistochemical (IHC) testing; An HER2/CEP17 ratio of less than 2.0 or a HER2 gene copy number of less than 4, as assessed by in situ hybridization (ISH), was confirmed by site investigator review.
•Receipt of any previous systemic anticancer therapy for focal recurrent or metastatic disease.
•Eastern Cooperative Oncology Group (ECOG) performance status of 0-
•Measurable lesions meeting RECIST 1.1 criteria or bone-only metastatic lesions (including osteolytic lesions or mixed osteolytic/osteogenic lesions).
•Adequate organ and bone marrow function, defined as neutrophil count (ANC) ≥ 1500/mm3(1.5 × 109/L) (no growth factor administration within 14 days); Platelet count (PLT) ≥ 100,000/mm3 (100 × 109/L) (no corrective therapy within 7 days); Hemoglobin (Hb) ≥ 9 g/dL (90 g/L) (no corrective therapy used within 7 days); Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 60 ml/min; Total bilirubin (BIL) ≤ 1.5 times upper limit of normal value (ULN); Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≤ 2.5 times The upper limit of normal (ULN), patients with liver metastases should be ≤ 5×ULN.
•Use of a medically approved contraceptive method (e.g., an intrauterine device, contraceptive pill, or condom) during the study treatment period and for 3 months after the end of the study treatment period for patients with potential childbearing potential; A negative serum HCG test must have been performed within 72 hours before study entry; And had to be non-lactating.
•All acute toxic effects prior to antineoplastic therapy resolved to grade 0-1 (according to NCICTCAE version 5.0) or to the level specified in the inclusion/exclusion criteria. Other toxicities, such as alopecia, that were deemed by the investigators not to pose a safety risk to patients were excluded.
•There is no limit to the number of previous lines of endocrine therapy.
•The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion Criteria

•Previous pathological diagnosis of HER2-positive. Patients who were not candidates for endocrine therapy as judged by the investigator. "Patients were included who were symptomatic, had spread to the viscera, and were at risk for life-threatening complications in the short term (including patients with uncontrolled massive exudates [thoracic, pericardial, abdominal], pulmonary lymphangitis, and more than 50% liver involvement)." 3.Patients with brain metastases diagnosed by head CT or MRI. 4.Patients had received any previous CDK4/6 inhibitor therapy. 5.Major surgery, chemotherapy, radiation therapy, any investigational drug, or other anticancer treatment within 2 weeks before study entry.
•6.Any other malignancy was diagnosed within 3 years before study entry, except nonmelanoma skin cancer, basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix treated with curative intent 7.Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥1000 IU/ml), hepatitis C (positive hepatitis C antibody and HCV-RNA higher than the lower limit of detection of the assay), or co-infection with hepatitis B and C.
•8.In the 6 months prior to study entry, the following occurred: Myocardial infarction, severe
•or unstable angina, cardiac dysfunction of NYHA class 2 or higher, persistent arrhythmia of class 2 or higher (according to NCICTCAE, version 5.0), atrial fibrillation of any grade, coronary or peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism).
•9.Severe infection (e.g., intravenous antibiotics, antifungal, or antiviral agents according to standard practice) within 4 weeks before the first dose or unexplained fever >38.5oC during screening/before the first dose.
•10.Inability to swallow, intestinal obstruction, or other factors affecting drug administration and absorption.
•11.Known allergies to letrozole or anastrozole, LHRH agonist (goserelin), SHR6390/ placebo, or any excipients.
•12.Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
•13.Known history of psychotropic drug abuse or drug use. 14.Patients with other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study or interfere with the study results, and those who are considered by the investigator to be unsuitable for participation in the study

Arms & Interventions

Dalpiciclib+letrozole

Experimental

Drug: Dalpiciclib 150mg qd, d1-21, q4w Letrozole 2.5mg qd, q4w

Intervention: Dalpiciclib plus letrozole (Drug)

Outcomes

Primary Outcomes

6-month PFS rate

Time Frame: From the start of randomization to 6 months

according to RECIST1.1 criteria,the percent of participant whose PFS is more than 6 months

Secondary Outcomes

Objective Response Rate（ORR）(From the start of randomization to a minimum of 1 year)
Disease Control Rate (DCR)(From the start of randomization to a minimum of 1 year)
Overall Survival(OS)(up to 2 years)
Progression-free survival(PFS)(From the start of randomization to a minimum of 1 year)
Duration of response（DOR）(From the start of randomization to a minimum of 1 year)

Investigators

Sponsor

Fengzhi Feng

Sponsor Class

Other

Responsible Party

Sponsor Investigator

Principal Investigator

Fengzhi Feng

professor

Peking Union Medical College Hospital

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting

Phase 4

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast CancerBreast Cancer

NCT06613373Jiangsu Famous Medical Technology Co., Ltd.30

Withdrawn

Phase 2

Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationCOVID-19

NCT05371275biotx.ai GmbH

Completed

Phase 1

PALBOCICLIB + PD-0325901 for NSCLC & Solid TumorsKRAS Mutant Non-Small Cell Lung CancerSolid Tumors

NCT02022982Dana-Farber Cancer Institute60

Unknown

Phase 2

Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerSolid Tumor

NCT05512780Hebei Medical University Fourth Hospital30

Terminated

Phase 1

NCT02255461Pediatric Brain Tumor Consortium35